FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3205035114> ?p ?o ?g. }

• W3205035114 abstract "<h3>Introduction/Background*</h3> Pembrolizumab conferred a 57% objective response rate (ORR) in patients with mismatch repair deficient (MMRd) advanced endometrial cancer (EC). However, the majority of patients with advanced disease have no specific molecular profile (NSMP) tumours or p53-abnormal (p53abn). We hypothesized that pembrolizumab with an inducer of immunogenic cell death such as doxorubicin could improve clinical responses and survival in all EC molecular subtypes. <h3>Methodology</h3> The TOPIC study (NCT03276013) was an investigator-initiated, single-arm, multi-centre, phase II study in patients with recurrent/metastatic EC who received one prior line of platinum-based chemotherapy. Patients received doxorubicin 60 mg/m² IV every 3 weeks for up to 9 cycles in combination with pembrolizumab 200 mg IV every 3 weeks up to 36 cycles, or until progression or toxicity. Tumour samples were analysed before treatment. Immunohistochemistry was performed for mismatch repair proteins and p53. Single-gene sequencing was used to detect polymerase-ɛ (POLE) exonuclease domain mutations. Primary outcome was progression-free survival rate at 6 months (PFS6). Subgroups were assessed relative to the primary outcome, ORR, median overall survival (OS), and 18-months OS rate. <h3>Result(s)*</h3> Molecular classification could be determined in 44 out of 48 patients included. As defined in the protocol, carcinosarcoma patients (n=6) were considered an exploratory cohort and were excluded from this analysis. In the non-carcinosarcoma cohort (n=38) median age was 66 years (range 37–80). Five (11.4%) patients were MMRd, 10 (22.7%) NSMP and 23 (52.3%) p53abn. No patient with POLE-mutated tumour was enrolled. Fifty-eight patients had endometroid EC, 42% serous carcinoma. Histologic grade at diagnosis: grade 1, 12.2%; grade 2, 21.1% and grade 3, 44.6%. Median follow-up at data cut-off was 19.1 months. Overall PFS6 was 59.3% (95%CI 45.4%-77.6%) with a median PFS of 6.5 months. Efficacy data according to patients’ molecular subtype are shown (see table 1). Overall, the NSMP subtype showed the better efficacy results (PFS6 of 78% and 40% ORR). <h3>Conclusion*</h3> Pembrolizumab plus doxorubicin exhibited promising antitumor activity in women with advanced EC after failure to platinum therapy, even in those patients that were not MMRd." @default.
• W3205035114 created "2021-10-25" @default.
• W3205035114 creator A5004741487 @default.
• W3205035114 creator A5007606531 @default.
• W3205035114 creator A5008201013 @default.
• W3205035114 creator A5023230423 @default.
• W3205035114 creator A5028946644 @default.
• W3205035114 creator A5034382940 @default.
• W3205035114 creator A5048092551 @default.
• W3205035114 creator A5059168069 @default.
• W3205035114 creator A5060787566 @default.
• W3205035114 creator A5061371368 @default.
• W3205035114 creator A5062377492 @default.
• W3205035114 creator A5067053417 @default.
• W3205035114 creator A5069482220 @default.
• W3205035114 creator A5071644127 @default.
• W3205035114 creator A5078445284 @default.
• W3205035114 creator A5081736939 @default.
• W3205035114 creator A5083979745 @default.
• W3205035114 creator A5086888445 @default.
• W3205035114 creator A5029260477 @default.
• W3205035114 date "2021-10-01" @default.
• W3205035114 modified "2023-10-17" @default.
• W3205035114 title "731 Biomarker analysis of the phase 2 study of pembrolizumab in combination with doxorubicin in advanced endometrial cancer: TOPIC trial/VHIO10001" @default.
• W3205035114 doi "https://doi.org/10.1136/ijgc-2021-esgo.187" @default.
• W3205035114 hasPublicationYear "2021" @default.
• W3205035114 type Work @default.
• W3205035114 sameAs 3205035114 @default.
• W3205035114 citedByCount "0" @default.
• W3205035114 crossrefType "proceedings-article" @default.
• W3205035114 hasAuthorship W3205035114A5004741487 @default.
• W3205035114 hasAuthorship W3205035114A5007606531 @default.
• W3205035114 hasAuthorship W3205035114A5008201013 @default.
• W3205035114 hasAuthorship W3205035114A5023230423 @default.
• W3205035114 hasAuthorship W3205035114A5028946644 @default.
• W3205035114 hasAuthorship W3205035114A5029260477 @default.
• W3205035114 hasAuthorship W3205035114A5034382940 @default.
• W3205035114 hasAuthorship W3205035114A5048092551 @default.
• W3205035114 hasAuthorship W3205035114A5059168069 @default.
• W3205035114 hasAuthorship W3205035114A5060787566 @default.
• W3205035114 hasAuthorship W3205035114A5061371368 @default.
• W3205035114 hasAuthorship W3205035114A5062377492 @default.
• W3205035114 hasAuthorship W3205035114A5067053417 @default.
• W3205035114 hasAuthorship W3205035114A5069482220 @default.
• W3205035114 hasAuthorship W3205035114A5071644127 @default.
• W3205035114 hasAuthorship W3205035114A5078445284 @default.
• W3205035114 hasAuthorship W3205035114A5081736939 @default.
• W3205035114 hasAuthorship W3205035114A5083979745 @default.
• W3205035114 hasAuthorship W3205035114A5086888445 @default.
• W3205035114 hasBestOaLocation W32050351141 @default.
• W3205035114 hasConcept C121608353 @default.
• W3205035114 hasConcept C126322002 @default.
• W3205035114 hasConcept C143998085 @default.
• W3205035114 hasConcept C2777088508 @default.
• W3205035114 hasConcept C2777546739 @default.
• W3205035114 hasConcept C2777701055 @default.
• W3205035114 hasConcept C2778938455 @default.
• W3205035114 hasConcept C2780057760 @default.
• W3205035114 hasConcept C71924100 @default.
• W3205035114 hasConcept C72563966 @default.
• W3205035114 hasConcept C90924648 @default.
• W3205035114 hasConceptScore W3205035114C121608353 @default.
• W3205035114 hasConceptScore W3205035114C126322002 @default.
• W3205035114 hasConceptScore W3205035114C143998085 @default.
• W3205035114 hasConceptScore W3205035114C2777088508 @default.
• W3205035114 hasConceptScore W3205035114C2777546739 @default.
• W3205035114 hasConceptScore W3205035114C2777701055 @default.
• W3205035114 hasConceptScore W3205035114C2778938455 @default.
• W3205035114 hasConceptScore W3205035114C2780057760 @default.
• W3205035114 hasConceptScore W3205035114C71924100 @default.
• W3205035114 hasConceptScore W3205035114C72563966 @default.
• W3205035114 hasConceptScore W3205035114C90924648 @default.
• W3205035114 hasLocation W32050351141 @default.
• W3205035114 hasOpenAccess W3205035114 @default.
• W3205035114 hasPrimaryLocation W32050351141 @default.
• W3205035114 hasRelatedWork W3186092871 @default.
• W3205035114 hasRelatedWork W3213113842 @default.
• W3205035114 hasRelatedWork W4200199918 @default.
• W3205035114 hasRelatedWork W4296459315 @default.
• W3205035114 hasRelatedWork W4307299108 @default.
• W3205035114 hasRelatedWork W4310768577 @default.
• W3205035114 hasRelatedWork W4313340213 @default.
• W3205035114 hasRelatedWork W4320155982 @default.
• W3205035114 hasRelatedWork W4327850169 @default.
• W3205035114 hasRelatedWork W4328052611 @default.
• W3205035114 isParatext "false" @default.
• W3205035114 isRetracted "false" @default.
• W3205035114 magId "3205035114" @default.
• W3205035114 workType "article" @default.